Prevalence of Epstein-Barr Virus Reactivation in Pregnancy

ABSTRACT

Recent evidence suggests a link between Epstein-Barr virus (EBV) reactivation and chronic stress in nonpregnant adults, possibly due to decreased cellular immune response. Our objective was to determine the prevalence of EBV seropositivity in a diverse cohort of pregnant women and whether maternal demographic characteristics were associated with EBV reactivation. In this cross-sectional study, we evaluated midpregnancy serum specimens from 64 healthy pregnant women for presence of EBV viral capsid antigen, EBV nuclear antigen, and EBV early antigen. The subjects were reported as EBV seronegative, EBV seropositive with reactivation, and EBV seropositive without reactivation. The maternal demographics of the seropositive women with EBV reactivation were compared with their nonreactivated counterparts. Chi-square and Student t test were used for statistical analysis. In our pregnant cohort, 63 (98%) of the 64 women were EBV seropositive. Among these seropositive women, 22 (35%) women demonstrated EBV reactivation in pregnancy. EBV reactivation was not associated with maternal age, race, parity, or insurance type. In our diverse pregnant cohort, 98% of women analyzed were EBV seropositive with 35% demonstrating EBV reactivation in the pregnancy by the second trimester. The pathophysiology and clinical implications of EBV reactivation during pregnancy need further study.

KEYWORDS

Epstein-Barr virus - EBV - reactivation - pregnancy - stress

REFERENCES

• 1 Eskild A, Bruu A L, Stray-Pedersen B, Jenum P. Epstein-Barr virus infection during pregnancy and the risk of adverse pregnancy outcome.  BJOG. 2005;  112 1620-1624
• 2 Godbout J P, Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer.  J Neuroimmune Pharmacol. 2006;  1 421-427
• 3 Glaser R, Pearl D K, Kiecolt-Glaser J K, Malarkey W B. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress.  Psychoneuroendocrinology. 1994;  19 765-772
• 4 Glaser R, Friedman S B, Smyth J et al.. The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point.  Brain Behav Immun. 1999;  13 240-251
• 5 Pierson D L, Stowe R P, Phillips T M, Lugg D J, Mehta S K. Epstein-Barr virus shedding by astronauts during space flight.  Brain Behav Immun. 2005;  19 235-242
• 6 Purtilo D T, Sakamoto K. Reactivation of Epstein-Barr virus in pregnant women: social factors, and immune competence as determinants of lymphoproliferative diseases—a hypothesis.  Med Hypotheses. 1982;  8 401-408
• 7 Avgil M, Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Ornoy A. Epstein-Barr virus infection in pregnancy—a prospective controlled study.  Reprod Toxicol. 2008;  25 468-471
• 8 Trogstad L I, Eskild A, Bruu A L, Jeansson S, Jenum P A. Is preeclampsia an infectious disease?.  Acta Obstet Gynecol Scand. 2001;  80 1036-1038
• 9 Fachiroh J, Paramita D K, Hariwiyanto B et al.. Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.  J Clin Microbiol. 2006;  44 1459-1467
• 10 Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization.  Scand J Clin Lab Invest. 2004;  64 535-545
• 11 Henry JB, Davey FR, Herman CJ, et al Clinical Diagnosis and Management by Laboratory Methods. Philadelphia; W.B. Saunders 2001: 1083
• 12 Glaser R, Kutz L A, MacCullum R C, Malarkey W B. Hormonal modulation of Epstein-Barr virus replication.  Neuroendocrinology. 1995;  62(4) 356-361